Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.

IF 2.3 Q2 RESPIRATORY SYSTEM Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI:10.1183/20734735.0039-2024
Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans
{"title":"Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.","authors":"Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans","doi":"10.1183/20734735.0039-2024","DOIUrl":null,"url":null,"abstract":"<p><p>Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented. Based on this assumption, prospective and a few randomised phase II studies have been performed, which suggested that adding a local ablative treatment to the systemic one can be a new option for selected stage IV NSCLC. The European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) supported efforts to define oligometastatic NSCLC to unify the semantics within the thoracic oncology community. This article summarises the currently available data and emphasises the questions and perspectives in oligometastatic disease NSCLC in European patient cohorts.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348918/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breathe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/20734735.0039-2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented. Based on this assumption, prospective and a few randomised phase II studies have been performed, which suggested that adding a local ablative treatment to the systemic one can be a new option for selected stage IV NSCLC. The European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) supported efforts to define oligometastatic NSCLC to unify the semantics within the thoracic oncology community. This article summarises the currently available data and emphasises the questions and perspectives in oligometastatic disease NSCLC in European patient cohorts.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IV 期非小细胞肺癌治疗:寡转移疾病与疾病进展,解开心结。
IV期非小细胞肺癌(NSCLC)是一个异质性患者群体,根据肿瘤生物学特征(组织学、PD-L1表达、基因组改变、转移部位)和患者特征(表现状态、合并症)决定是否对其进行全身治疗。在大多数情况下,建议采用某种系统性治疗方法,基于免疫疗法或靶向疗法被认为是2024年的治疗标准。寡转移性 NSCLC 代表了从局部疾病到转移性疾病这一生物学过程中的一个特定概念,在这一过程中,只有数量有限的转移部位可以被记录下来。基于这一假设,前瞻性研究和一些随机II期研究表明,在全身治疗的基础上增加局部消融治疗,可以成为部分IV期NSCLC患者的新选择。欧洲癌症研究与治疗组织(EORTC)和欧洲放射治疗与肿瘤学会(ESTRO)支持对少转移 NSCLC 进行定义,以统一胸部肿瘤学界的语义。本文总结了目前可用的数据,并强调了欧洲患者队列中寡转移性 NSCLC 疾病的问题和前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breathe
Breathe RESPIRATORY SYSTEM-
CiteScore
2.90
自引率
5.00%
发文量
51
审稿时长
12 weeks
期刊最新文献
Controversies in the clinical management of chronic pulmonary aspergillosis. Large-scale education in respiratory medicine: content versus delivery. Lung imaging methods: indications, strengths and limitations. Pulmonary complications of bone marrow transplantation. Spatial lung imaging in clinical and translational settings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1